denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Daiichi Sankyo, Inc., Seattle Genetics, and Takeda Oncology
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Biological, antibodies, Diseases, Therapies, Combinations, biopsy, Adverse Events, Biological Processes, T-Cell Lymphoma, Technology and Procedures, immunotherapy, Lymphoid Malignancies, genomics, genetic profiling, Clinically relevant, imaging, molecular testing, NGS, pathogenesis, pathways
Hematology Disease Topics & Pathways:
Biological, antibodies, Diseases, Therapies, Combinations, biopsy, Adverse Events, Biological Processes, T-Cell Lymphoma, Technology and Procedures, immunotherapy, Lymphoid Malignancies, genomics, genetic profiling, Clinically relevant, imaging, molecular testing, NGS, pathogenesis, pathways
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Steven M. Horwitz, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Horwitz: Celgene: Research Funding; Kyowa Hakko Kirin: Consultancy, Research Funding; Millennium/Takeda: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Trillium: Research Funding; Innate Pharma: Consultancy; miRagen: Consultancy; Mundipharma: Consultancy; Portola: Research Funding; BeiGene: Consultancy; Affimed: Consultancy; Infinity/Verastem: Research Funding; Forty Seven: Consultancy, Research Funding; Aileron: Consultancy, Research Funding; ADC Therapeutics: Consultancy, Research Funding.
Speakers:
Ahmet Dogan, MD, PhD, Memorial Sloan Kettering Cancer Center
,
Neha Mehta-Shah, MD, Washington University School of St. Louis
and
Pamela B. Allen, MD, MSc, Assistant Professor, Department of Hematology and Medical Oncology, Attending Physician, Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute
Disclosures:
Dogan: Roche: Consultancy, Research Funding; National Cancer Institute: Research Funding; AbbVie: Consultancy; EUSA Pharma: Consultancy; Takeda: Consultancy; Seattle Genetics: Consultancy; Corvus Pharmaceuticals: Consultancy; Physicians Education Resource: Consultancy. Mehta-Shah: Kyowa Kirin: Consultancy; Verastem: Research Funding; Karyopharm Therapeutics: Consultancy; Innate Pharmaceuticals: Research Funding; Celgene: Research Funding; Genetech: Research Funding; C4 Therapeutics: Consultancy; Bristol Myers-Squibb: Research Funding. Allen: Research to Practice: Speakers Bureau; Curio Sciences: Honoraria; Imbrium: Consultancy, Other; Bayer: Consultancy, Other; Clinical Care Options: Consultancy.
This activity will bring together renowned international experts in T-cell lymphoma treatment and clinical research in for an in-depth mock tumor board that will assess the clinical impact of recent and emerging trial data in PTCL and CTCL. A series of case presentations will be presented with clinical trial data tightly integrated to illuminate T-cell lymphoma diagnosis and treatment decisions related to front-line and beyond therapies, sequencing, switching and patient and disease characteristics. Adverse events and management will be educationally tied to appropriate presentations. Future directions in the field will also be addressed and considered regarding how recent developments and highly anticipated trials may shape care in the future.
Faculty will be present onstage throughout the program. Audience participation will be integrated throughout to encourage interaction with faculty and engagement with the content.
The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting.
See more of: Satellite Symposia